Executive summary The past six decades have seen remarkable improvements in health
outcomes for people with cystic fibrosis, which was once a fatal disease of infants and young …

Small and medium-sized enterprises (SMEs) are a significant source of employment for
many people in developing and developed economies. However, one of the significant …

Background Elexacaftor plus tezacaftor plus ivacaftor is a triple-combination cystic fibrosis
transmembrane conductance regulator (CFTR) modulator regimen shown to be generally …

Pseudomonas aeruginosa (P. aeruginosa) is a ubiquitous and opportunistic microorganism
and is considered one of the most significant pathogens that produce chronic colonization …

Highly effective CFTR modulator drug therapy is increasingly available to those with cystic
fibrosis. Multiple observational research studies are now being conducted to better …

Rationale: A 24-week, phase 3, open-label study showed elexacaftor/tezacaftor/ivacaftor
(ELX/TEZ/IVA) was safe and efficacious in children aged 6–11 years with cystic fibrosis (CF) …

Cystic fibrosis (CF) is an autosomal recessive genetic disorder characterized by dysfunction
of the CFTR gene. It is a multisystem disease that most often affects White individuals. In …

RESUMO A fibrose cística (FC) é uma doença genética autossômica recessiva
caracterizada pela disfunção do gene CFTR. Trata-se de uma doença multissistêmica que …

BACKGROUND: People with cystic fibrosis face substantial physical, psychological, and
social challenges as they move into adolescence and adulthood, which are likely to impact …

This is the third in a series of four papers updating the European Cystic Fibrosis Society
(ECFS) standards for the care of people with CF. This paper focuses on recognising and …